CVT-130
Prevention of anthracycline‑induced cardiotoxicity
IND‑cleared (Phase 1 planned)Active
Key Facts
Indication
Prevention of anthracycline‑induced cardiotoxicity
Phase
IND‑cleared (Phase 1 planned)
Status
Active
Company
About Corventum
Developing first‑in‑class small molecules to protect the heart from cancer‑treatment toxicity.
View full company profile